These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 11106246

  • 1. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
    Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, Brünner N.
    Clin Cancer Res; 2000 Nov; 6(11):4292-9. PubMed ID: 11106246
    [Abstract] [Full Text] [Related]

  • 2. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A, Höyhtyä M, Tavelin B, Stenling R, Lindmark G.
    Anticancer Res; 2000 Nov; 20(2B):1085-91. PubMed ID: 10810401
    [Abstract] [Full Text] [Related]

  • 3. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R.
    Anticancer Res; 2000 Nov; 20(6D):5195-8. PubMed ID: 11326694
    [Abstract] [Full Text] [Related]

  • 4. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.
    Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Høyer-Hansen G, Brünner N, Stephens RW.
    Br J Cancer; 1999 May; 80(3-4):495-503. PubMed ID: 10408859
    [Abstract] [Full Text] [Related]

  • 5. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer.
    Yukawa N, Yoshikawa T, Akaike M, Sugimasa Y, Takemiya S, Yanoma S, Imada T, Noguchi Y.
    Anticancer Res; 2004 May; 24(3b):2101-5. PubMed ID: 15274408
    [Abstract] [Full Text] [Related]

  • 6. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
    Sørensen NM, Schrohl AS, Jensen V, Christensen IJ, Nielsen HJ, Brünner N.
    Scand J Gastroenterol; 2008 May; 43(2):186-91. PubMed ID: 18224564
    [Abstract] [Full Text] [Related]

  • 7. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
    Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Pahl H, Fateh-Moghadam A.
    Anticancer Res; 1997 May; 17(4B):2935-8. PubMed ID: 9329568
    [Abstract] [Full Text] [Related]

  • 8. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R, Stephens RW, Brünner N, Christensen IJ, Nielsen HJ, Heilmann L, von Tempelhoff GF.
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [Abstract] [Full Text] [Related]

  • 9. Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer.
    Kos J, Nielsen HJ, Krasovec M, Christensen IJ, Cimerman N, Stephens RW, Brünner N.
    Clin Cancer Res; 1998 Jun; 4(6):1511-6. PubMed ID: 9626470
    [Abstract] [Full Text] [Related]

  • 10. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma.
    Yukawa N, Yoshikawa T, Akaike M, Sugimasa Y, Takemiya S, Yanoma S, Noguchi Y, Takanashi Y.
    Br J Surg; 2001 Dec; 88(12):1596-601. PubMed ID: 11736971
    [Abstract] [Full Text] [Related]

  • 11. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis.
    Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brünner N.
    Clin Cancer Res; 2000 Feb; 6(2):505-11. PubMed ID: 10690531
    [Abstract] [Full Text] [Related]

  • 12. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
    Wang CS, Wu TL, Tsao KC, Sun CF.
    Ann Clin Lab Sci; 2006 Feb; 36(1):23-30. PubMed ID: 16501233
    [Abstract] [Full Text] [Related]

  • 13. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.
    Holten-Andersen MN, Nielsen HJ, Sørensen S, Jensen V, Brünner N, Christensen IJ.
    Eur J Cancer; 2006 Aug; 42(12):1889-96. PubMed ID: 16809030
    [Abstract] [Full Text] [Related]

  • 14. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer.
    Yukawa N, Yoshikawa T, Akaike M, Sugimasa Y, Rino Y, Masuda M, Imada T.
    Oncology; 2007 Aug; 72(3-4):205-8. PubMed ID: 18160809
    [Abstract] [Full Text] [Related]

  • 15. Changes in plasma TIMP-1 levels after resection for primary colorectal cancer.
    Frederiksen C, Lomholt AF, Davis GJ, Dowell BL, Blankenstein MA, Christensen IJ, Brünner N, Nielsen HJ.
    Anticancer Res; 2009 Jan; 29(1):75-81. PubMed ID: 19331135
    [Abstract] [Full Text] [Related]

  • 16. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients.
    Ishida H, Murata N, Hayashi Y, Tada M, Hashimoto D.
    Surg Today; 2003 Jan; 33(12):885-92. PubMed ID: 14669077
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer.
    Miyazaki T, Okada N, Ishibashi K, Ogata K, Ohsawa T, Ishiguro T, Nakada H, Yokoyama M, Matsuki M, Kato H, Kuwano H, Ishida H.
    Jpn J Clin Oncol; 2008 Dec; 38(12):839-43. PubMed ID: 18923001
    [Abstract] [Full Text] [Related]

  • 18. Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer.
    Frederiksen C, Lykke J, Christensen IJ, Brünner N, Nielsen HJ.
    Scand J Clin Lab Invest; 2007 Dec; 67(5):545-52. PubMed ID: 17763191
    [Abstract] [Full Text] [Related]

  • 19. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
    Waas ET, Wobbes T, Ruers T, Lomme RM, Hendriks T.
    Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
    [Abstract] [Full Text] [Related]

  • 20. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
    Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, Brown-Shimer S, Pierce K, Carney W.
    Cancer; 2007 May 15; 109(10):1933-9. PubMed ID: 17407159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.